- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
European Consortium Aims to Validate Blood-Based Cancer Biomarkers
The consortium, called CANCER-ID, is a partnership between 33 organizations across 13 European nations focused on establishing the clinical utility of liquid biopsies in patients with NSCLC and HER2-resistant breast cancer.
Blood-based biomarkers such as circulating tumor cells, circulating free DNA, circulating tumor DNA, and microRNAs are potential indicators for the tumor burden of patients living with cancer. Identification and analysis of these markers from blood is still exploratory, but they may offer an additional and extremely useful tool for modern anti-cancer therapy. Blood based tests are not only very useful when biopsies of the tumor are not feasible (ie, limited access to tumor, etc), but also such blood-based tests may allow a close follow-up, and thereby offer a way to monitor the efficacy of treatment and potentially improve the choice of treatment options.
€
€
CANCER-ID is a newly formed European consortium funded by the Innovative Medicines Initiative (IMI) with currently 33 partners from 13 countries with the common goal of establishing standard protocols for clinical validation of blood-based biomarkers. In this unique setting, experts from all walks of cancer clinical research, eg academic and clinical research, innovative Small-to-Medium sized Enterprises, diagnostics companies, and the pharmaceutical industry, will work together to establish the clinical utility of “liquid biopsies” in patients with Non-Small Cell Lung Cancer or Her2-therapy resistant breast cancer. The consortium’s industrial partners are currently contributing 8.2 million to the project, and these funds are complemented the IMI Joint Undertaking for a combined 14.5 million budget.
Link to the complete article:
Source: EORTC
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
